Jo Latimer (pictured above), head of neurosciences and mental health at the UK’s Medical Research Council (MRC), has been appointed chief scientific officer at a charity performing research in the dementia field.
Beginning mid-August, Dr Latimer will take up the role with the UK Dementia Research Institute (UK DRI), a multimillion-pound investment which is principally funded by MRC.
During 17 years with MRC, Dr Latimer has held responsibilities for scientific areas in neurodegeneration, neurophysiology and translational research as well as leading on industry liaison.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze